||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Glaxosmithkline Share Discussion Threads
Showing 18976 to 18998 of 19000 messages
|GSK expects to supply up to 40 million doses across both vaccines for the US market in the 2016-17 season. One hundred percent of GSK supply is quadrivalent doses.|
|Reinvestment of dividends at a guess.|
|What's all the director share holdings about|
|BEIJING--China's Food and Drug Administration approved GlaxoSmithKline PLC's (GSK) Cervarix, the first vaccine against human papilloma virus to be licensed for use in China for the prevention of cervical cancer.
The approval is expected to boost the sales of the U.K.-based drug company in China after its business there was severely hit by a bribery scandal three years ago.
Glaxo said Cervarix was tested on 6,000 subjects for a span of six years in China. It is registered in China for use in girls and women between nine and 25 years old. The commercial launch of Cervarix is expected in early 2017.|
|£20 was going through my mind,and Bingo up pops Jeffries upgrade,and a 4% yield,is correct,and still about the FTSE 100 average.Predicted 1650,and now £20 also now.|
|For once some analyst is talking some sense, as he is saying what I said two weeks ago (post 12925). LOL.
GlaxoSmithKline shares have further to go
Pharmaceutical giant GlaxoSmithKline (GSK) has been upgraded on the back of its improving yield.
Jefferies analyst Jeffrey Holford upgraded his recommendation from ‘hold’ to ‘buy’ and increased the target price from £16.50 to £20.00. The shares fell 1.1% to £16.48 yesterday.
‘GSK’s 4.9% dividend yield is becoming increasingly well covered as its earnings rise, helped by recent foreign exchange movements, a strong performance from [HIV treatment subsidiary] ViiV and better than expected margin progression,’ he said.
‘We believe that fears of a dividend cut associated with the appointment of a new chief executive are overdone and that the macro environment (falling bond yields) could see the shares driven up to a 4% dividend yield.’|
|Downtrend from 1998 to 2013 would be broken with a close above 1700 - bwtfdik|
|Strange - I got my div yesterday|
|Yes this has been a real money cow ;)
Dividends,special dividends and a big share price boost to boot!
Luckily its my biggest holding.
If only all my investments had done this well!|
|TM, good position to be in, well done.|
|I can look after it for you :)|
|Well, I have another massive GSK dividend payment coming next week. I usually enjoy re-investing it by purchasing more GSK shares, but this time around, after the recent climb, I'm not so sure. Maybe I'll hold it and wait for a possible drop at the next xd point (11 Aug?), and then buy.|
|well that is me out for 1650.
Entered at 1400 plus the divis makes it one of my best trades of the last year!
The £ seems to have stabilised Vs $ so not much more arbitrage to play there.|
|After months of work under the radar, GlaxoSmithKline committed to entering the Zika R&D field, announcing on Thursday that it’s pairing with the National Institutes of Health in a project based at its new vaccine research hub in Rockville, MD.|
|I topped up yesterday - my thinking being although it costs more for us here in the UK to buy shares GSK ADR's are now cheaper to buy in US. Combined with pound weakness will increase the likelihood of a takeover bid|
|Why? Do you think it has much further to go in the short term (from the falling pound?)?|
|Bought back yesterday some of those I sold..to add to those I hold from £13's|
|A great currency hedge. When I have a moment I shall compare against my currency switches in the spot market - I expect will be close.|
|These are my biggest holding great to see them flying at last.
Talking heads on cnbc saying they see further sterling falls which should help.
Still tempted to take some of table as I think ftse 7k will be tough to break again and could see some profit taking infact I still think ftse 6k could be seen again in next year or sooner no doubt pulling these down with it and be nice to have some cash available to take advantage.|
|Great, beats £17 yesterday.|
|Broker note out from AlphaValue this morning... Https://www.research-tree.com/company/GB0009252882
"Q1 16 revenue came in ahead of our expectations with revenue growth of 8% (all revenue growth numbers at CER unless specified otherwise) to £6.2bn. FX tailwinds added another 3pp to the growth. HIV (+57%) remained the saving grace in the pharma business, and covered up the 9% decline in the non-HIV business, limiting the division’s decline to 1% (although it grew by 5% pro forma). It was followed by Consumer Healthcare (+26%) and Vaccines (+23%, 14% pro forma). The new products – HIV (Tivicay, Triumeq), respiratory (Relvar/Breo, Anoro, Incruse, Nucala) and meningitis vaccines (Menveo, Bexsero) – generated sales of £821m (Q4 15: £682m, Q1 15: £269m), contributing 20% to the Pharma division sales (vs 16.5% in Q4)."|